

COVID-19 Impact on Global ENG(Endoglin precursor), Market Insights and Forecast to 2026

<https://marketpublishers.com/r/C532EE60C736EN.html>

Date: September 2020

Pages: 189

Price: US\$ 3,900.00 (Single User License)

ID: C532EE60C736EN

Abstracts

ENG(Endoglin precursor) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global ENG(Endoglin precursor) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the ENG(Endoglin precursor) market is segmented into

Above 90%

Above 95%

Above 99%

Others

Segment by Application, the ENG(Endoglin precursor) market is segmented into

Biopharmaceutical Companies

Hospitals

Bioscience Research Institutions

Others

Regional and Country-level Analysis

The ENG(Endoglin precursor) market is analysed and market size information is provided by regions (countries).

The key regions covered in the ENG(Endoglin precursor) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and ENG(Endoglin precursor) Market Share Analysis

ENG(Endoglin precursor) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in ENG(Endoglin precursor) business, the date to enter into the ENG(Endoglin precursor) market, ENG(Endoglin precursor) product introduction, recent developments, etc.

The major vendors covered:

Aviva Systems Biology Corporation(USA)

Atlas Antibodies(Sweden)

Abbexa Ltd(UK)

Abiocode(US)

Boster Biological Technology(USA)

Biobyte(UK)

Bio-Rad(US)

Bioss Antibodies(US)

Biosensis(US)

BioLegend(US)

BioVision(US)

BethylLaboratories(US)

Epigentek(US)

EnzoLifeSciences(Switzerland)

Genetex(US)

Lifespan Biosciences(US)

Novus Biologicals(US)

Proteintech(US)

ProSci(US)

ProteoGenix(France)

R&D Systems(US)

Rockland(US)

St John's Laboratory Ltd(UK)

Stemcell(Canada)

Thermo Fisher Scientific(US)

USBiological(US)

Contents

1 STUDY COVERAGE

- 1.1 ENG(Endoglin precursor) Product Introduction
- 1.2 Market Segments
- 1.3 Key ENG(Endoglin precursor) Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
 - 1.4.1 Global ENG(Endoglin precursor) Market Size Growth Rate by Type
 - 1.4.2 Above 90%
 - 1.4.3 Above 95%
 - 1.4.4 Above 99%
 - 1.4.5 Others
- 1.5 Market by Application
 - 1.5.1 Global ENG(Endoglin precursor) Market Size Growth Rate by Application
 - 1.5.2 Biopharmaceutical Companies
 - 1.5.3 Hospitals
 - 1.5.4 Bioscience Research Institutions
 - 1.5.5 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): ENG(Endoglin precursor) Industry Impact
 - 1.6.1 How the Covid-19 is Affecting the ENG(Endoglin precursor) Industry
 - 1.6.1.1 ENG(Endoglin precursor) Business Impact Assessment - Covid-19
 - 1.6.1.2 Supply Chain Challenges
 - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
 - 1.6.2 Market Trends and ENG(Endoglin precursor) Potential Opportunities in the COVID-19 Landscape
 - 1.6.3 Measures / Proposal against Covid-19
 - 1.6.3.1 Government Measures to Combat Covid-19 Impact
 - 1.6.3.2 Proposal for ENG(Endoglin precursor) Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

2 EXECUTIVE SUMMARY

- 2.1 Global ENG(Endoglin precursor) Market Size Estimates and Forecasts
 - 2.1.1 Global ENG(Endoglin precursor) Revenue 2015-2026
 - 2.1.2 Global ENG(Endoglin precursor) Sales 2015-2026
- 2.2 ENG(Endoglin precursor) Market Size by Region: 2020 Versus 2026
 - 2.2.1 Global ENG(Endoglin precursor) Retrospective Market Scenario in Sales by

Region: 2015-2020

2.2.2 Global ENG(Endoglin precursor) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 GLOBAL ENG(ENDOGLIN PRECURSOR) COMPETITOR LANDSCAPE BY PLAYERS

3.1 ENG(Endoglin precursor) Sales by Manufacturers

3.1.1 ENG(Endoglin precursor) Sales by Manufacturers (2015-2020)

3.1.2 ENG(Endoglin precursor) Sales Market Share by Manufacturers (2015-2020)

3.2 ENG(Endoglin precursor) Revenue by Manufacturers

3.2.1 ENG(Endoglin precursor) Revenue by Manufacturers (2015-2020)

3.2.2 ENG(Endoglin precursor) Revenue Share by Manufacturers (2015-2020)

3.2.3 Global ENG(Endoglin precursor) Market Concentration Ratio (CR5 and HHI) (2015-2020)

3.2.4 Global Top 10 and Top 5 Companies by ENG(Endoglin precursor) Revenue in 2019

3.2.5 Global ENG(Endoglin precursor) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.3 ENG(Endoglin precursor) Price by Manufacturers

3.4 ENG(Endoglin precursor) Manufacturing Base Distribution, Product Types

3.4.1 ENG(Endoglin precursor) Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers ENG(Endoglin precursor) Product Type

3.4.3 Date of International Manufacturers Enter into ENG(Endoglin precursor) Market

3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global ENG(Endoglin precursor) Market Size by Type (2015-2020)

4.1.1 Global ENG(Endoglin precursor) Sales by Type (2015-2020)

4.1.2 Global ENG(Endoglin precursor) Revenue by Type (2015-2020)

4.1.3 ENG(Endoglin precursor) Average Selling Price (ASP) by Type (2015-2026)

4.2 Global ENG(Endoglin precursor) Market Size Forecast by Type (2021-2026)

4.2.1 Global ENG(Endoglin precursor) Sales Forecast by Type (2021-2026)

4.2.2 Global ENG(Endoglin precursor) Revenue Forecast by Type (2021-2026)

4.2.3 ENG(Endoglin precursor) Average Selling Price (ASP) Forecast by Type (2021-2026)

4.3 Global ENG(Endoglin precursor) Market Share by Price Tier (2015-2020): Low-End,

Mid-Range and High-End

5 BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global ENG(Endoglin precursor) Market Size by Application (2015-2020)

5.1.1 Global ENG(Endoglin precursor) Sales by Application (2015-2020)

5.1.2 Global ENG(Endoglin precursor) Revenue by Application (2015-2020)

5.1.3 ENG(Endoglin precursor) Price by Application (2015-2020)

5.2 ENG(Endoglin precursor) Market Size Forecast by Application (2021-2026)

5.2.1 Global ENG(Endoglin precursor) Sales Forecast by Application (2021-2026)

5.2.2 Global ENG(Endoglin precursor) Revenue Forecast by Application (2021-2026)

5.2.3 Global ENG(Endoglin precursor) Price Forecast by Application (2021-2026)

6 NORTH AMERICA

6.1 North America ENG(Endoglin precursor) by Country

6.1.1 North America ENG(Endoglin precursor) Sales by Country

6.1.2 North America ENG(Endoglin precursor) Revenue by Country

6.1.3 U.S.

6.1.4 Canada

6.2 North America ENG(Endoglin precursor) Market Facts & Figures by Type

6.3 North America ENG(Endoglin precursor) Market Facts & Figures by Application

7 EUROPE

7.1 Europe ENG(Endoglin precursor) by Country

7.1.1 Europe ENG(Endoglin precursor) Sales by Country

7.1.2 Europe ENG(Endoglin precursor) Revenue by Country

7.1.3 Germany

7.1.4 France

7.1.5 U.K.

7.1.6 Italy

7.1.7 Russia

7.2 Europe ENG(Endoglin precursor) Market Facts & Figures by Type

7.3 Europe ENG(Endoglin precursor) Market Facts & Figures by Application

8 ASIA PACIFIC

8.1 Asia Pacific ENG(Endoglin precursor) by Region

- 8.1.1 Asia Pacific ENG(Endoglin precursor) Sales by Region
- 8.1.2 Asia Pacific ENG(Endoglin precursor) Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam

8.2 Asia Pacific ENG(Endoglin precursor) Market Facts & Figures by Type

8.3 Asia Pacific ENG(Endoglin precursor) Market Facts & Figures by Application

9 LATIN AMERICA

9.1 Latin America ENG(Endoglin precursor) by Country

- 9.1.1 Latin America ENG(Endoglin precursor) Sales by Country
- 9.1.2 Latin America ENG(Endoglin precursor) Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina

9.2 Central & South America ENG(Endoglin precursor) Market Facts & Figures by Type

9.3 Central & South America ENG(Endoglin precursor) Market Facts & Figures by Application

10 MIDDLE EAST AND AFRICA

10.1 Middle East and Africa ENG(Endoglin precursor) by Country

- 10.1.1 Middle East and Africa ENG(Endoglin precursor) Sales by Country
- 10.1.2 Middle East and Africa ENG(Endoglin precursor) Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E

10.2 Middle East and Africa ENG(Endoglin precursor) Market Facts & Figures by Type

10.3 Middle East and Africa ENG(Endoglin precursor) Market Facts & Figures by Application

11 COMPANY PROFILES

11.1 Aviva Systems Biology Corporation(USA)

11.1.1 Aviva Systems Biology Corporation(USA) Corporation Information

11.1.2 Aviva Systems Biology Corporation(USA) Description, Business Overview and Total Revenue

11.1.3 Aviva Systems Biology Corporation(USA) Sales, Revenue and Gross Margin (2015-2020)

11.1.4 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Products Offered

11.1.5 Aviva Systems Biology Corporation(USA) Recent Development

11.2 Atlas Antibodies(Sweden)

11.2.1 Atlas Antibodies(Sweden) Corporation Information

11.2.2 Atlas Antibodies(Sweden) Description, Business Overview and Total Revenue

11.2.3 Atlas Antibodies(Sweden) Sales, Revenue and Gross Margin (2015-2020)

11.2.4 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Products Offered

11.2.5 Atlas Antibodies(Sweden) Recent Development

11.3 Abbexa Ltd(UK)

11.3.1 Abbexa Ltd(UK) Corporation Information

11.3.2 Abbexa Ltd(UK) Description, Business Overview and Total Revenue

11.3.3 Abbexa Ltd(UK) Sales, Revenue and Gross Margin (2015-2020)

11.3.4 Abbexa Ltd(UK) ENG(Endoglin precursor) Products Offered

11.3.5 Abbexa Ltd(UK) Recent Development

11.4 Abiocode(US)

11.4.1 Abiocode(US) Corporation Information

11.4.2 Abiocode(US) Description, Business Overview and Total Revenue

11.4.3 Abiocode(US) Sales, Revenue and Gross Margin (2015-2020)

11.4.4 Abiocode(US) ENG(Endoglin precursor) Products Offered

11.4.5 Abiocode(US) Recent Development

11.5 Boster Biological Technology(USA)

11.5.1 Boster Biological Technology(USA) Corporation Information

11.5.2 Boster Biological Technology(USA) Description, Business Overview and Total Revenue

11.5.3 Boster Biological Technology(USA) Sales, Revenue and Gross Margin (2015-2020)

11.5.4 Boster Biological Technology(USA) ENG(Endoglin precursor) Products Offered

11.5.5 Boster Biological Technology(USA) Recent Development

11.6 Biobyte(UK)

- 11.6.1 Biobyte(UK) Corporation Information
- 11.6.2 Biobyte(UK) Description, Business Overview and Total Revenue
- 11.6.3 Biobyte(UK) Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Biobyte(UK) ENG(Endoglin precursor) Products Offered
- 11.6.5 Biobyte(UK) Recent Development
- 11.7 Bio-Rad(US)
 - 11.7.1 Bio-Rad(US) Corporation Information
 - 11.7.2 Bio-Rad(US) Description, Business Overview and Total Revenue
 - 11.7.3 Bio-Rad(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.7.4 Bio-Rad(US) ENG(Endoglin precursor) Products Offered
 - 11.7.5 Bio-Rad(US) Recent Development
- 11.8 Bioss Antibodies(US)
 - 11.8.1 Bioss Antibodies(US) Corporation Information
 - 11.8.2 Bioss Antibodies(US) Description, Business Overview and Total Revenue
 - 11.8.3 Bioss Antibodies(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.8.4 Bioss Antibodies(US) ENG(Endoglin precursor) Products Offered
 - 11.8.5 Bioss Antibodies(US) Recent Development
- 11.9 Biosensis(US)
 - 11.9.1 Biosensis(US) Corporation Information
 - 11.9.2 Biosensis(US) Description, Business Overview and Total Revenue
 - 11.9.3 Biosensis(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.9.4 Biosensis(US) ENG(Endoglin precursor) Products Offered
 - 11.9.5 Biosensis(US) Recent Development
- 11.10 BioLegend(US)
 - 11.10.1 BioLegend(US) Corporation Information
 - 11.10.2 BioLegend(US) Description, Business Overview and Total Revenue
 - 11.10.3 BioLegend(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.10.4 BioLegend(US) ENG(Endoglin precursor) Products Offered
 - 11.10.5 BioLegend(US) Recent Development
- 11.1 Aviva Systems Biology Corporation(USA)
 - 11.1.1 Aviva Systems Biology Corporation(USA) Corporation Information
 - 11.1.2 Aviva Systems Biology Corporation(USA) Description, Business Overview and Total Revenue
 - 11.1.3 Aviva Systems Biology Corporation(USA) Sales, Revenue and Gross Margin (2015-2020)
 - 11.1.4 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Products Offered
 - 11.1.5 Aviva Systems Biology Corporation(USA) Recent Development
- 11.12 Bethyl Laboratories(US)

- 11.12.1 BethylLaboratories(US) Corporation Information
- 11.12.2 BethylLaboratories(US) Description, Business Overview and Total Revenue
- 11.12.3 BethylLaboratories(US) Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 BethylLaboratories(US) Products Offered
- 11.12.5 BethylLaboratories(US) Recent Development
- 11.13 Epigentek(US)
 - 11.13.1 Epigentek(US) Corporation Information
 - 11.13.2 Epigentek(US) Description, Business Overview and Total Revenue
 - 11.13.3 Epigentek(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.13.4 Epigentek(US) Products Offered
 - 11.13.5 Epigentek(US) Recent Development
- 11.14 EnzoLifeSciences(Switzerland)
 - 11.14.1 EnzoLifeSciences(Switzerland) Corporation Information
 - 11.14.2 EnzoLifeSciences(Switzerland) Description, Business Overview and Total Revenue
 - 11.14.3 EnzoLifeSciences(Switzerland) Sales, Revenue and Gross Margin (2015-2020)
 - 11.14.4 EnzoLifeSciences(Switzerland) Products Offered
 - 11.14.5 EnzoLifeSciences(Switzerland) Recent Development
- 11.15 Genetex(US)
 - 11.15.1 Genetex(US) Corporation Information
 - 11.15.2 Genetex(US) Description, Business Overview and Total Revenue
 - 11.15.3 Genetex(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.15.4 Genetex(US) Products Offered
 - 11.15.5 Genetex(US) Recent Development
- 11.16 Lifespan Biosciences(US)
 - 11.16.1 Lifespan Biosciences(US) Corporation Information
 - 11.16.2 Lifespan Biosciences(US) Description, Business Overview and Total Revenue
 - 11.16.3 Lifespan Biosciences(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.16.4 Lifespan Biosciences(US) Products Offered
 - 11.16.5 Lifespan Biosciences(US) Recent Development
- 11.17 Novus Biologicals(US)
 - 11.17.1 Novus Biologicals(US) Corporation Information
 - 11.17.2 Novus Biologicals(US) Description, Business Overview and Total Revenue
 - 11.17.3 Novus Biologicals(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.17.4 Novus Biologicals(US) Products Offered
 - 11.17.5 Novus Biologicals(US) Recent Development
- 11.18 Proteintech(US)
 - 11.18.1 Proteintech(US) Corporation Information

- 11.18.2 Proteintech(US) Description, Business Overview and Total Revenue
- 11.18.3 Proteintech(US) Sales, Revenue and Gross Margin (2015-2020)
- 11.18.4 Proteintech(US) Products Offered
- 11.18.5 Proteintech(US) Recent Development
- 11.19 ProSci(US)
 - 11.19.1 ProSci(US) Corporation Information
 - 11.19.2 ProSci(US) Description, Business Overview and Total Revenue
 - 11.19.3 ProSci(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.19.4 ProSci(US) Products Offered
 - 11.19.5 ProSci(US) Recent Development
- 11.20 ProteoGenix(France)
 - 11.20.1 ProteoGenix(France) Corporation Information
 - 11.20.2 ProteoGenix(France) Description, Business Overview and Total Revenue
 - 11.20.3 ProteoGenix(France) Sales, Revenue and Gross Margin (2015-2020)
 - 11.20.4 ProteoGenix(France) Products Offered
 - 11.20.5 ProteoGenix(France) Recent Development
- 11.21 R&D Systems(US)
 - 11.21.1 R&D Systems(US) Corporation Information
 - 11.21.2 R&D Systems(US) Description, Business Overview and Total Revenue
 - 11.21.3 R&D Systems(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.21.4 R&D Systems(US) Products Offered
 - 11.21.5 R&D Systems(US) Recent Development
- 11.22 Rockland(US)
 - 11.22.1 Rockland(US) Corporation Information
 - 11.22.2 Rockland(US) Description, Business Overview and Total Revenue
 - 11.22.3 Rockland(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.22.4 Rockland(US) Products Offered
 - 11.22.5 Rockland(US) Recent Development
- 11.23 St John's Laboratory Ltd(UK)
 - 11.23.1 St John's Laboratory Ltd(UK) Corporation Information
 - 11.23.2 St John's Laboratory Ltd(UK) Description, Business Overview and Total Revenue
 - 11.23.3 St John's Laboratory Ltd(UK) Sales, Revenue and Gross Margin (2015-2020)
 - 11.23.4 St John's Laboratory Ltd(UK) Products Offered
 - 11.23.5 St John's Laboratory Ltd(UK) Recent Development
- 11.24 Stemcell(Canada)
 - 11.24.1 Stemcell(Canada) Corporation Information
 - 11.24.2 Stemcell(Canada) Description, Business Overview and Total Revenue
 - 11.24.3 Stemcell(Canada) Sales, Revenue and Gross Margin (2015-2020)

- 11.24.4 Stemcell(Canada) Products Offered
- 11.24.5 Stemcell(Canada) Recent Development
- 11.25 Thermo Fisher Scientific(US)
 - 11.25.1 Thermo Fisher Scientific(US) Corporation Information
 - 11.25.2 Thermo Fisher Scientific(US) Description, Business Overview and Total Revenue
 - 11.25.3 Thermo Fisher Scientific(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.25.4 Thermo Fisher Scientific(US) Products Offered
 - 11.25.5 Thermo Fisher Scientific(US) Recent Development
- 11.26 USBiological(US)
 - 11.26.1 USBiological(US) Corporation Information
 - 11.26.2 USBiological(US) Description, Business Overview and Total Revenue
 - 11.26.3 USBiological(US) Sales, Revenue and Gross Margin (2015-2020)
 - 11.26.4 USBiological(US) Products Offered
 - 11.26.5 USBiological(US) Recent Development

12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)

- 12.1 ENG(Endoglin precursor) Market Estimates and Projections by Region
 - 12.1.1 Global ENG(Endoglin precursor) Sales Forecast by Regions 2021-2026
 - 12.1.2 Global ENG(Endoglin precursor) Revenue Forecast by Regions 2021-2026
- 12.2 North America ENG(Endoglin precursor) Market Size Forecast (2021-2026)
 - 12.2.1 North America: ENG(Endoglin precursor) Sales Forecast (2021-2026)
 - 12.2.2 North America: ENG(Endoglin precursor) Revenue Forecast (2021-2026)
 - 12.2.3 North America: ENG(Endoglin precursor) Market Size Forecast by Country (2021-2026)
- 12.3 Europe ENG(Endoglin precursor) Market Size Forecast (2021-2026)
 - 12.3.1 Europe: ENG(Endoglin precursor) Sales Forecast (2021-2026)
 - 12.3.2 Europe: ENG(Endoglin precursor) Revenue Forecast (2021-2026)
 - 12.3.3 Europe: ENG(Endoglin precursor) Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific ENG(Endoglin precursor) Market Size Forecast (2021-2026)
 - 12.4.1 Asia Pacific: ENG(Endoglin precursor) Sales Forecast (2021-2026)
 - 12.4.2 Asia Pacific: ENG(Endoglin precursor) Revenue Forecast (2021-2026)
 - 12.4.3 Asia Pacific: ENG(Endoglin precursor) Market Size Forecast by Region (2021-2026)
- 12.5 Latin America ENG(Endoglin precursor) Market Size Forecast (2021-2026)
 - 12.5.1 Latin America: ENG(Endoglin precursor) Sales Forecast (2021-2026)
 - 12.5.2 Latin America: ENG(Endoglin precursor) Revenue Forecast (2021-2026)

12.5.3 Latin America: ENG(Endoglin precursor) Market Size Forecast by Country (2021-2026)

12.6 Middle East and Africa ENG(Endoglin precursor) Market Size Forecast (2021-2026)

12.6.1 Middle East and Africa: ENG(Endoglin precursor) Sales Forecast (2021-2026)

12.6.2 Middle East and Africa: ENG(Endoglin precursor) Revenue Forecast (2021-2026)

12.6.3 Middle East and Africa: ENG(Endoglin precursor) Market Size Forecast by Country (2021-2026)

13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS

13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Porter's Five Forces Analysis

13.5 Primary Interviews with Key ENG(Endoglin precursor) Players (Opinion Leaders)

14 VALUE CHAIN AND SALES CHANNELS ANALYSIS

14.1 Value Chain Analysis

14.2 ENG(Endoglin precursor) Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

List Of Tables

LIST OF TABLES

- Table 1. ENG(Endoglin precursor) Market Segments
- Table 2. Ranking of Global Top ENG(Endoglin precursor) Manufacturers by Revenue (US\$ Million) in 2019
- Table 3. Global ENG(Endoglin precursor) Market Size Growth Rate by Type 2020-2026 (K MT) & (US\$ Million)
- Table 4. Major Manufacturers of Above 90%
- Table 5. Major Manufacturers of Above 95%
- Table 6. Major Manufacturers of Above 99%
- Table 7. Major Manufacturers of Others
- Table 8. COVID-19 Impact Global Market: (Four ENG(Endoglin precursor) Market Size Forecast Scenarios)
- Table 9. Opportunities and Trends for ENG(Endoglin precursor) Players in the COVID-19 Landscape
- Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 11. Key Regions/Countries Measures against Covid-19 Impact
- Table 12. Proposal for ENG(Endoglin precursor) Players to Combat Covid-19 Impact
- Table 13. Global ENG(Endoglin precursor) Market Size Growth Rate by Application 2020-2026 (K MT)
- Table 14. Global ENG(Endoglin precursor) Market Size by Region (K MT) & (US\$ Million): 2020 VS 2026
- Table 15. Global ENG(Endoglin precursor) Sales by Regions 2015-2020 (K MT)
- Table 16. Global ENG(Endoglin precursor) Sales Market Share by Regions (2015-2020)
- Table 17. Global ENG(Endoglin precursor) Revenue by Regions 2015-2020 (US\$ Million)
- Table 18. Global ENG(Endoglin precursor) Sales by Manufacturers (2015-2020) (K MT)
- Table 19. Global ENG(Endoglin precursor) Sales Share by Manufacturers (2015-2020)
- Table 20. Global ENG(Endoglin precursor) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
- Table 21. Global ENG(Endoglin precursor) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ENG(Endoglin precursor) as of 2019)
- Table 22. ENG(Endoglin precursor) Revenue by Manufacturers (2015-2020) (US\$ Million)
- Table 23. ENG(Endoglin precursor) Revenue Share by Manufacturers (2015-2020)
- Table 24. Key Manufacturers ENG(Endoglin precursor) Price (2015-2020) (USD/MT)
- Table 25. ENG(Endoglin precursor) Manufacturers Manufacturing Base Distribution and

Headquarters

Table 26. Manufacturers ENG(Endoglin precursor) Product Type

Table 27. Date of International Manufacturers Enter into ENG(Endoglin precursor) Market

Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 29. Global ENG(Endoglin precursor) Sales by Type (2015-2020) (K MT)

Table 30. Global ENG(Endoglin precursor) Sales Share by Type (2015-2020)

Table 31. Global ENG(Endoglin precursor) Revenue by Type (2015-2020) (US\$ Million)

Table 32. Global ENG(Endoglin precursor) Revenue Share by Type (2015-2020)

Table 33. ENG(Endoglin precursor) Average Selling Price (ASP) by Type 2015-2020 (USD/MT)

Table 34. Global ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 35. Global ENG(Endoglin precursor) Sales Share by Application (2015-2020)

Table 36. North America ENG(Endoglin precursor) Sales by Country (2015-2020) (K MT)

Table 37. North America ENG(Endoglin precursor) Sales Market Share by Country (2015-2020)

Table 38. North America ENG(Endoglin precursor) Revenue by Country (2015-2020) (US\$ Million)

Table 39. North America ENG(Endoglin precursor) Revenue Market Share by Country (2015-2020)

Table 40. North America ENG(Endoglin precursor) Sales by Type (2015-2020) (K MT)

Table 41. North America ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)

Table 42. North America ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 43. North America ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)

Table 44. Europe ENG(Endoglin precursor) Sales by Country (2015-2020) (K MT)

Table 45. Europe ENG(Endoglin precursor) Sales Market Share by Country (2015-2020)

Table 46. Europe ENG(Endoglin precursor) Revenue by Country (2015-2020) (US\$ Million)

Table 47. Europe ENG(Endoglin precursor) Revenue Market Share by Country (2015-2020)

Table 48. Europe ENG(Endoglin precursor) Sales by Type (2015-2020) (K MT)

Table 49. Europe ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)

Table 50. Europe ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 51. Europe ENG(Endoglin precursor) Sales Market Share by Application

(2015-2020)

Table 52. Asia Pacific ENG(Endoglin precursor) Sales by Region (2015-2020) (K MT)

Table 53. Asia Pacific ENG(Endoglin precursor) Sales Market Share by Region (2015-2020)

Table 54. Asia Pacific ENG(Endoglin precursor) Revenue by Region (2015-2020) (US\$ Million)

Table 55. Asia Pacific ENG(Endoglin precursor) Revenue Market Share by Region (2015-2020)

Table 56. Asia Pacific ENG(Endoglin precursor) Sales by Type (2015-2020) (K MT)

Table 57. Asia Pacific ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)

Table 58. Asia Pacific ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 59. Asia Pacific ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)

Table 60. Latin America ENG(Endoglin precursor) Sales by Country (2015-2020) (K MT)

Table 61. Latin America ENG(Endoglin precursor) Sales Market Share by Country (2015-2020)

Table 62. Latin Americaa ENG(Endoglin precursor) Revenue by Country (2015-2020) (US\$ Million)

Table 63. Latin America ENG(Endoglin precursor) Revenue Market Share by Country (2015-2020)

Table 64. Latin America ENG(Endoglin precursor) Sales by Type (2015-2020) (K MT)

Table 65. Latin America ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)

Table 66. Latin America ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 67. Latin America ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)

Table 68. Middle East and Africa ENG(Endoglin precursor) Sales by Country (2015-2020) (K MT)

Table 69. Middle East and Africa ENG(Endoglin precursor) Sales Market Share by Country (2015-2020)

Table 70. Middle East and Africa ENG(Endoglin precursor) Revenue by Country (2015-2020) (US\$ Million)

Table 71. Middle East and Africa ENG(Endoglin precursor) Revenue Market Share by Country (2015-2020)

Table 72. Middle East and Africa ENG(Endoglin precursor) Sales by Type (2015-2020)

(K MT)

Table 73. Middle East and Africa ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)

Table 74. Middle East and Africa ENG(Endoglin precursor) Sales by Application (2015-2020) (K MT)

Table 75. Middle East and Africa ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)

Table 76. Aviva Systems Biology Corporation(USA) Corporation Information

Table 77. Aviva Systems Biology Corporation(USA) Description and Major Businesses

Table 78. Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 79. Aviva Systems Biology Corporation(USA) Product

Table 80. Aviva Systems Biology Corporation(USA) Recent Development

Table 81. Atlas Antibodies(Sweden) Corporation Information

Table 82. Atlas Antibodies(Sweden) Description and Major Businesses

Table 83. Atlas Antibodies(Sweden) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 84. Atlas Antibodies(Sweden) Product

Table 85. Atlas Antibodies(Sweden) Recent Development

Table 86. Abbexa Ltd(UK) Corporation Information

Table 87. Abbexa Ltd(UK) Description and Major Businesses

Table 88. Abbexa Ltd(UK) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 89. Abbexa Ltd(UK) Product

Table 90. Abbexa Ltd(UK) Recent Development

Table 91. Abiocode(US) Corporation Information

Table 92. Abiocode(US) Description and Major Businesses

Table 93. Abiocode(US) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 94. Abiocode(US) Product

Table 95. Abiocode(US) Recent Development

Table 96. Boster Biological Technology(USA) Corporation Information

Table 97. Boster Biological Technology(USA) Description and Major Businesses

Table 98. Boster Biological Technology(USA) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 99. Boster Biological Technology(USA) Product

Table 100. Boster Biological Technology(USA) Recent Development

Table 101. Biobyte(UK) Corporation Information

- Table 102. Biobyte(UK) Description and Major Businesses
- Table 103. Biobyte(UK) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 104. Biobyte(UK) Product
- Table 105. Biobyte(UK) Recent Development
- Table 106. Bio-Rad(US) Corporation Information
- Table 107. Bio-Rad(US) Description and Major Businesses
- Table 108. Bio-Rad(US) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 109. Bio-Rad(US) Product
- Table 110. Bio-Rad(US) Recent Development
- Table 111. Bioss Antibodies(US) Corporation Information
- Table 112. Bioss Antibodies(US) Description and Major Businesses
- Table 113. Bioss Antibodies(US) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 114. Bioss Antibodies(US) Product
- Table 115. Bioss Antibodies(US) Recent Development
- Table 116. Biosensis(US) Corporation Information
- Table 117. Biosensis(US) Description and Major Businesses
- Table 118. Biosensis(US) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 119. Biosensis(US) Product
- Table 120. Biosensis(US) Recent Development
- Table 121. BioLegend(US) Corporation Information
- Table 122. BioLegend(US) Description and Major Businesses
- Table 123. BioLegend(US) ENG(Endoglin precursor) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 124. BioLegend(US) Product
- Table 125. BioLegend(US) Recent Development
- Table 126. BioVision(US) Corporation Information
- Table 127. BioVision(US) Description and Major Businesses
- Table 128. BioVision(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 129. BioVision(US) Product
- Table 130. BioVision(US) Recent Development
- Table 131. BethylLaboratories(US) Corporation Information
- Table 132. BethylLaboratories(US) Description and Major Businesses
- Table 133. BethylLaboratories(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

- Table 134. BethylLaboratories(US) Product
- Table 135. BethylLaboratories(US) Recent Development
- Table 136. Epigentek(US) Corporation Information
- Table 137. Epigentek(US) Description and Major Businesses
- Table 138. Epigentek(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 139. Epigentek(US) Product
- Table 140. Epigentek(US) Recent Development
- Table 141. EnzoLifeSciences(Switzerland) Corporation Information
- Table 142. EnzoLifeSciences(Switzerland) Description and Major Businesses
- Table 143. EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 144. EnzoLifeSciences(Switzerland) Product
- Table 145. EnzoLifeSciences(Switzerland) Recent Development
- Table 146. Genetex(US) Corporation Information
- Table 147. Genetex(US) Description and Major Businesses
- Table 148. Genetex(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 149. Genetex(US) Product
- Table 150. Genetex(US) Recent Development
- Table 151. Lifespan Biosciences(US) Corporation Information
- Table 152. Lifespan Biosciences(US) Description and Major Businesses
- Table 153. Lifespan Biosciences(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 154. Lifespan Biosciences(US) Product
- Table 155. Lifespan Biosciences(US) Recent Development
- Table 156. Novus Biologicals(US) Corporation Information
- Table 157. Novus Biologicals(US) Description and Major Businesses
- Table 158. Novus Biologicals(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 159. Novus Biologicals(US) Product
- Table 160. Novus Biologicals(US) Recent Development
- Table 161. Proteintech(US) Corporation Information
- Table 162. Proteintech(US) Description and Major Businesses
- Table 163. Proteintech(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 164. Proteintech(US) Product
- Table 165. Proteintech(US) Recent Development
- Table 166. ProSci(US) Corporation Information

Table 167. ProSci(US) Description and Major Businesses

Table 168. ProSci(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 169. ProSci(US) Product

Table 170. ProSci(US) Recent Development

Table 171. ProteoGenix(France) Corporation Information

Table 172. ProteoGenix(France) Description and Major Businesses

Table 173. ProteoGenix(France) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 174. ProteoGenix(France) Product

Table 175. ProteoGenix(France) Recent Development

Table 176. R&D Systems(US) Corporation Information

Table 177. R&D Systems(US) Description and Major Businesses

Table 178. R&D Systems(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 179. R&D Systems(US) Product

Table 180. R&D Systems(US) Recent Development

Table 181. Rockland(US) Corporation Information

Table 182. Rockland(US) Description and Major Businesses

Table 183. Rockland(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 184. Rockland(US) Product

Table 185. Rockland(US) Recent Development

Table 186. St John's Laboratory Ltd(UK) Corporation Information

Table 187. St John's Laboratory Ltd(UK) Description and Major Businesses

Table 188. St John's Laboratory Ltd(UK) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 189. St John's Laboratory Ltd(UK) Product

Table 190. St John's Laboratory Ltd(UK) Recent Development

Table 191. Stemcell(Canada) Corporation Information

Table 192. Stemcell(Canada) Description and Major Businesses

Table 193. Stemcell(Canada) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 194. Stemcell(Canada) Product

Table 195. Stemcell(Canada) Recent Development

Table 196. Thermo Fisher Scientific(US) Corporation Information

Table 197. Thermo Fisher Scientific(US) Description and Major Businesses

Table 198. Thermo Fisher Scientific(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)

- Table 199. Thermo Fisher Scientific(US) Product
- Table 200. Thermo Fisher Scientific(US) Recent Development
- Table 201. USBiological(US) Corporation Information
- Table 202. USBiological(US) Description and Major Businesses
- Table 203. USBiological(US) ENG(Endoglin precursor) Sales (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2015-2020)
- Table 204. USBiological(US) Product
- Table 205. USBiological(US) Recent Development
- Table 206. Global ENG(Endoglin precursor) Sales Forecast by Regions (2021-2026) (K MT)
- Table 207. Global ENG(Endoglin precursor) Sales Market Share Forecast by Regions (2021-2026)
- Table 208. Global ENG(Endoglin precursor) Revenue Forecast by Regions (2021-2026) (US\$ Million)
- Table 209. Global ENG(Endoglin precursor) Revenue Market Share Forecast by Regions (2021-2026)
- Table 210. North America: ENG(Endoglin precursor) Sales Forecast by Country (2021-2026) (K MT)
- Table 211. North America: ENG(Endoglin precursor) Revenue Forecast by Country (2021-2026) (US\$ Million)
- Table 212. Europe: ENG(Endoglin precursor) Sales Forecast by Country (2021-2026) (K MT)
- Table 213. Europe: ENG(Endoglin precursor) Revenue Forecast by Country (2021-2026) (US\$ Million)
- Table 214. Asia Pacific: ENG(Endoglin precursor) Sales Forecast by Region (2021-2026) (K MT)
- Table 215. Asia Pacific: ENG(Endoglin precursor) Revenue Forecast by Region (2021-2026) (US\$ Million)
- Table 216. Latin America: ENG(Endoglin precursor) Sales Forecast by Country (2021-2026) (K MT)
- Table 217. Latin America: ENG(Endoglin precursor) Revenue Forecast by Country (2021-2026) (US\$ Million)
- Table 218. Middle East and Africa: ENG(Endoglin precursor) Sales Forecast by Country (2021-2026) (K MT)
- Table 219. Middle East and Africa: ENG(Endoglin precursor) Revenue Forecast by Country (2021-2026) (US\$ Million)
- Table 220. Key Opportunities and Drivers: Impact Analysis (2021-2026)
- Table 221. Key Challenges
- Table 222. Market Risks

Table 223. Main Points Interviewed from Key ENG(Endoglin precursor) Players

Table 224. ENG(Endoglin precursor) Customers List

Table 225. ENG(Endoglin precursor) Distributors List

Table 226. Research Programs/Design for This Report

Table 227. Key Data Information from Secondary Sources

Table 228. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. ENG(Endoglin precursor) Product Picture
- Figure 2. Global ENG(Endoglin precursor) Sales Market Share by Type in 2020 & 2026
- Figure 3. Above 90% Product Picture
- Figure 4. Above 95% Product Picture
- Figure 5. Above 99% Product Picture
- Figure 6. Others Product Picture
- Figure 7. Global ENG(Endoglin precursor) Sales Market Share by Application in 2020 & 2026
- Figure 8. Biopharmaceutical Companies
- Figure 9. Hospitals
- Figure 10. Bioscience Research Institutions
- Figure 11. Others
- Figure 12. ENG(Endoglin precursor) Report Years Considered
- Figure 13. Global ENG(Endoglin precursor) Market Size 2015-2026 (US\$ Million)
- Figure 14. Global ENG(Endoglin precursor) Sales 2015-2026 (K MT)
- Figure 15. Global ENG(Endoglin precursor) Market Size Market Share by Region: 2020 Versus 2026
- Figure 16. Global ENG(Endoglin precursor) Sales Market Share by Region (2015-2020)
- Figure 17. Global ENG(Endoglin precursor) Sales Market Share by Region in 2019
- Figure 18. Global ENG(Endoglin precursor) Revenue Market Share by Region (2015-2020)
- Figure 19. Global ENG(Endoglin precursor) Revenue Market Share by Region in 2019
- Figure 20. Global ENG(Endoglin precursor) Sales Share by Manufacturer in 2019
- Figure 21. The Top 10 and 5 Players Market Share by ENG(Endoglin precursor) Revenue in 2019
- Figure 22. ENG(Endoglin precursor) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
- Figure 23. Global ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
- Figure 24. Global ENG(Endoglin precursor) Sales Market Share by Type in 2019
- Figure 25. Global ENG(Endoglin precursor) Revenue Market Share by Type (2015-2020)
- Figure 26. Global ENG(Endoglin precursor) Revenue Market Share by Type in 2019
- Figure 27. Global ENG(Endoglin precursor) Market Share by Price Range (2015-2020)
- Figure 28. Global ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)

Figure 29. Global ENG(Endoglin precursor) Sales Market Share by Application in 2019

Figure 30. Global ENG(Endoglin precursor) Revenue Market Share by Application (2015-2020)

Figure 31. Global ENG(Endoglin precursor) Revenue Market Share by Application in 2019

Figure 32. North America ENG(Endoglin precursor) Sales Growth Rate 2015-2020 (K MT)

Figure 33. North America ENG(Endoglin precursor) Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 34. North America ENG(Endoglin precursor) Sales Market Share by Country in 2019

Figure 35. North America ENG(Endoglin precursor) Revenue Market Share by Country in 2019

Figure 36. U.S. ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 37. U.S. ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 38. Canada ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 39. Canada ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 40. North America ENG(Endoglin precursor) Market Share by Type in 2019

Figure 41. North America ENG(Endoglin precursor) Market Share by Application in 2019

Figure 42. Europe ENG(Endoglin precursor) Sales Growth Rate 2015-2020 (K MT)

Figure 43. Europe ENG(Endoglin precursor) Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 44. Europe ENG(Endoglin precursor) Sales Market Share by Country in 2019

Figure 45. Europe ENG(Endoglin precursor) Revenue Market Share by Country in 2019

Figure 46. Germany ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 47. Germany ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 48. France ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 49. France ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 50. U.K. ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 51. U.K. ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 52. Italy ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 53. Italy ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 54. Russia ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 55. Russia ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 56. Europe ENG(Endoglin precursor) Market Share by Type in 2019

Figure 57. Europe ENG(Endoglin precursor) Market Share by Application in 2019

Figure 58. Asia Pacific ENG(Endoglin precursor) Sales Growth Rate 2015-2020 (K MT)

Figure 59. Asia Pacific ENG(Endoglin precursor) Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 60. Asia Pacific ENG(Endoglin precursor) Sales Market Share by Region in 2019

Figure 61. Asia Pacific ENG(Endoglin precursor) Revenue Market Share by Region in 2019

Figure 62. China ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 63. China ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 64. Japan ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 65. Japan ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 66. South Korea ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 67. South Korea ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 68. India ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 69. India ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 70. Australia ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 71. Australia ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 72. Taiwan ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 73. Taiwan ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 74. Indonesia ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 75. Indonesia ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 76. Thailand ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 77. Thailand ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 78. Malaysia ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 79. Malaysia ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 80. Philippines ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 81. Philippines ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 82. Vietnam ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 83. Vietnam ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 84. Asia Pacific ENG(Endoglin precursor) Market Share by Type in 2019

Figure 85. Asia Pacific ENG(Endoglin precursor) Market Share by Application in 2019

Figure 86. Latin America ENG(Endoglin precursor) Sales Growth Rate 2015-2020 (K MT)

Figure 87. Latin America ENG(Endoglin precursor) Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 88. Latin America ENG(Endoglin precursor) Sales Market Share by Country in 2019

Figure 89. Latin America ENG(Endoglin precursor) Revenue Market Share by Country in 2019

Figure 90. Mexico ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 91. Mexico ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 92. Brazil ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 93. Brazil ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 94. Argentina ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 95. Argentina ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 96. Latin America ENG(Endoglin precursor) Market Share by Type in 2019

Figure 97. Latin America ENG(Endoglin precursor) Market Share by Application in 2019

Figure 98. Middle East and Africa ENG(Endoglin precursor) Sales Growth Rate 2015-2020 (K MT)

Figure 99. Middle East and Africa ENG(Endoglin precursor) Revenue Growth Rate 2015-2020 (US\$ Million)

Figure 100. Middle East and Africa ENG(Endoglin precursor) Sales Market Share by Country in 2019

Figure 101. Middle East and Africa ENG(Endoglin precursor) Revenue Market Share by Country in 2019

Figure 102. Turkey ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 103. Turkey ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 104. Saudi Arabia ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K

MT)

Figure 105. Saudi Arabia ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 106. U.A.E ENG(Endoglin precursor) Sales Growth Rate (2015-2020) (K MT)

Figure 107. U.A.E ENG(Endoglin precursor) Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 108. Middle East and Africa ENG(Endoglin precursor) Market Share by Type in 2019

Figure 109. Middle East and Africa ENG(Endoglin precursor) Market Share by Application in 2019

Figure 110. Aviva Systems Biology Corporation(USA) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 111. Atlas Antibodies(Sweden) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 112. Abbexa Ltd(UK) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 113. Abiocode(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 114. Boster Biological Technology(USA) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 115. Biobyte(UK) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 116. Bio-Rad(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 117. Bioss Antibodies(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 118. Biosensis(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 119. BioLegend(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 120. BioVision(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 121. BethylLaboratories(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 122. Epigentek(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 123. EnzoLifeSciences(Switzerland) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 124. Genetex(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 125. Lifespan Biosciences(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 126. Novus Biologicals(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 127. Proteintech(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 128. ProSci(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 129. ProteoGenix(France) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 130. R&D Systems(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 131. Rockland(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 132. St John's Laboratory Ltd(UK) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 133. Stemcell(Canada) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 134. Thermo Fisher Scientific(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 135. USBiological(US) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 136. North America ENG(Endoglin precursor) Sales Growth Rate Forecast (2021-2026) (K MT)

Figure 137. North America ENG(Endoglin precursor) Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 138. Europe ENG(Endoglin precursor) Sales Growth Rate Forecast (2021-2026) (K MT)

Figure 139. Europe ENG(Endoglin precursor) Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 140. Asia Pacific ENG(Endoglin precursor) Sales Growth Rate Forecast (2021-2026) (K MT)

Figure 141. Asia Pacific ENG(Endoglin precursor) Revenue Growth Rate Forecast (2021-2026) (US\$ Million)

Figure 1

I would like to order

Product name: COVID-19 Impact on Global ENG(Endoglin precursor), Market Insights and Forecast to 2026

Product link: <https://marketpublishers.com/r/C532EE60C736EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C532EE60C736EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

